-
Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis
•
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from China’s National Medical Products Administration (NMPA) for its Kangyueda (stapokibart), an anti-IL-4Rα monoclonal antibody (mAb), this time for its use in seasonal allergic rhinitis. Stapokibart previously gained NMPA approval for the treatment of severe atopic…
-
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study, demonstrating the benefit of Mim8 in 70 children (aged 1-11 years old) with hemophilia A, both with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment with the investigational drug, offering participants the option…
-
RemeGen’s Executive Director He Ruyi Resigns for Career Development
•
China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director and core technical personnel of the company, from his posts as executive Director of the second session of the Board, member of the strategic committee of the Board, and Chief Strategy Officer of the company,…
-
Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase III clinical study for its BL-M07D1. The randomized, controlled trial will assess BL-M07D1 versus trastuzumab emtansine as a postoperative adjuvant treatment for HER2-positive breast cancer…
-
AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its Emblaveo (aztreonam and avibactam). The drug is the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic approved for use in combination with metronidazole for patients 18…
-
Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II study assessing its polypeptide drug candidate RAY1225 in obese and overweight patients. This marks a significant step forward in the global development of…
-
Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth
•
Germany-based Siemens Healthineers AG (ETR: SHL) released its results for the first quarter of fiscal year 2025, ended December 31, 2024. The company showcased an excellent equipment book-to-bill ratio of 1.21 and comparable revenue growth of 5.7%. This marks a strong start to the fiscal year, driven by growth across…
-
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
•
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306 and BAT2506 have been accepted for review by China’s National Medical Products Administration (NMPA) and the European Medicines Agency (EMA), respectively. BAT2306 is a biosimilar version of Novartis’ (NYSE: NVS) Cosentyx (secukinumab), while BAT2506 is…
-
Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
•
Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal, led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team, values the business at approximately JPY 510 billion…
-
Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s Laboratories Ltd. (BOM: 500124) for its HLX15, a biosimilar version of Johnson & Johnson’s Darzalex (daratumumab). Under the agreement, Dr. Reddy’s will obtain exclusive commercialization rights to the anti-CD38 monoclonal antibody (mAb), including both intravenous…
-
Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches
•
China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market…
-
Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
•
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD 12.3 billion during Q4 2024, excluding foreign exchange impact. For the full year, revenues rose 7% YOY to USD 48.3 billion, according to the company’s financial report released this week. The US market expanded 9%…
-
CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA
•
China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for its adsorbed tetanus vaccine for review. The vaccine is indicated for the prevention of non-neonatal tetanus. This acceptance marks a significant milestone in the development and…
-
Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study for its interleukin-17 (IL-17) monoclonal antibody (mAb) HB0017 in hidradenitis suppurativa (HS) after receiving approval from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of novel treatments for…
-
Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease
•
China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) AA001. The drug is intended for the treatment of mild cognitive impairment caused by Alzheimer’s disease (AD) and mild to moderate AD. This…
-
Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL
•
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of the pivotal Phase III waveLINE-010 study. This study is designed to assess zilovertamab vedotin, an investigational antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with rituximab plus cyclophosphamide, doxorubicin, and…
-
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
•
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase III study assessing its Epidaza (chidamide) combined with CHOP in naive, peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH). This approval marks a significant step…
-
Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
•
Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that they have received approval from the National Medical Products Administration (NMPA) to conduct a Phase III clinical study for JSKN003 versus trastuzumab emtansine in HER2-positive advanced breast cancer. This approval marks a significant milestone in…
-
Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease
•
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from the National Medical Products Administration (NMPA) for its GC310, an adeno-associated virus (AAV) gene therapy for hepatolenticular degeneration, also known as Wilson’s disease. This approval marks a significant step forward in the development of a…
-
Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials
•
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HX044. This follows the initiation of a Phase I study for the CTLA-4 bispecific antibody (BsAb) in Australia. The approval marks a significant step in the global…
